Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108
Palisade Bio (NASDAQ:PALI) has released a Virtual Investor KOL Connect segment featuring Dr. Brian G. Feagan, a leading expert in Fibrostenotic Crohn's Disease (FSCD) and Inflammatory Bowel Diseases (IBD). The segment focuses on the company's lead candidate PALI-2108 and its potential impact on FSCD treatment.
Dr. Feagan, a Professor of Medicine at Western University and Senior Scientific Director at Alimentiv, Inc., discussed the significant unmet need in FSCD treatment and highlighted PALI-2108's novel approach. The drug candidate is designed to provide localized treatment that reduces side effects while maintaining anti-inflammatory and anti-fibrotic activity.
Palisade Bio (NASDAQ:PALI) ha pubblicato un segmento Virtual Investor KOL Connect con Dr. Brian G. Feagan, esperto di punta nella Malattia di Crohn fibrostenotica (FSCD) e nelle Malattie Infiammatorie Intestinali (IBD). Il segmento 猫 incentrato sul candidato principale dell'azienda, PALI-2108, e sul suo potenziale impatto nel trattamento della FSCD.
Il Dr. Feagan, Professore di Medicina alla Western University e Senior Scientific Director presso Alimentiv, Inc., ha sottolineato l'importante bisogno insoddisfatto nel trattamento della FSCD e ha illustrato l'approccio innovativo di PALI-2108. Il candidato farmaco 猫 concepito per offrire un trattamento localizzato che riduca gli effetti collaterali mantenendo attivit脿 antiinfiammatoria e antifibrotica.
Palisade Bio (NASDAQ:PALI) ha lanzado un segmento Virtual Investor KOL Connect con Dr. Brian G. Feagan, experto destacado en Enfermedad de Crohn fibroest茅nica (FSCD) y Enfermedades Inflamatorias Intestinales (IBD). El segmento se centra en el candidato principal de la compa帽铆a, PALI-2108, y su posible impacto en el tratamiento de la FSCD.
El Dr. Feagan, Profesor de Medicina en Western University y Director Cient铆fico Senior en Alimentiv, Inc., habl贸 sobre la considerable necesidad no cubierta en el tratamiento de la FSCD y destac贸 el enfoque novedoso de PALI-2108. El candidato est谩 dise帽ado para proporcionar un tratamiento localizado que reduzca los efectos secundarios manteniendo actividad antiinflamatoria y antifibr贸tica.
Palisade Bio (NASDAQ:PALI)電� 靹湢順戩癌靹� 韥氤�(FSCD) 氚� 鞐检靹� 鞛レ頇�(IBD) 攵勳暭鞚� 鞝�氇呿暅 鞝勲臧�鞚� Dr. Brian G. Feagan瓿检潣 Virtual Investor KOL Connect 鞓侅儊鞚� 瓿店皽頄堨姷雼堧嫟. 頃措嫻 鞓侅儊鞚� 須岇偓鞚� 欤检殧 頉勲炒氍检鞚� PALI-2108鞕� FSCD 旃橂鞐� 氙胳範 鞛犾灛鞝� 鞓來枼鞚� 雼る９雼堧嫟.
Western University 鞚橅暀 甑愳垬鞚挫瀽 Alimentiv, Inc.鞚� 靾橃劃 瓿柬暀 鞚挫偓鞚� Feagan 氚曥偓電� FSCD 旃橂鞐愳劀 於╈”霅橃 鞎婌潃 韥� 靾橃殧毳� 鞏戈笁頃橂┌ PALI-2108鞚� 順侅嫚鞝� 鞝戧芳氩曥潉 臧曥“頄堨姷雼堧嫟. 鞚� 鞎诫 頉勲炒電� 攵�鞛戩毄鞚� 欷勳澊氅挫劀 頃椉 氚� 頃劕鞙犿檾 頇滌劚鞚� 鞙犾頃橂姅 甑唽 旃橂毳� 鞝滉车頃橂弰搿� 靹り硠霅橃棃鞀惦媹雼�.
Palisade Bio (NASDAQ:PALI) a diffus茅 un segment Virtual Investor KOL Connect avec le Dr Brian G. Feagan, expert de premier plan sur la maladie de Crohn fibro-st茅nosante (FSCD) et les maladies inflammatoires de l'intestin (MII). Le segment se concentre sur le candidat principal de la soci茅t茅, PALI-2108, et son impact potentiel sur le traitement de la FSCD.
Le Dr Feagan, professeur de m茅decine 脿 la Western University et directeur scientifique principal chez Alimentiv, Inc., a 茅voqu茅 le besoin important non satisfait dans la prise en charge de la FSCD et a mis en avant l'approche novatrice de PALI-2108. Le candidat m茅dicament est con莽u pour offrir un traitement localis茅 r茅duisant les effets secondaires tout en conservant des activit茅s anti-inflammatoires et anti-fibrotiques.
Palisade Bio (NASDAQ:PALI) hat ein Virtual Investor KOL Connect-Segment mit Dr. Brian G. Feagan ver枚ffentlicht, einem f眉hrenden Experten f眉r fibrostenotische Crohn-Krankheit (FSCD) und entz眉ndliche Darmerkrankungen (IBD). Das Segment konzentriert sich auf den f眉hrenden Wirkstoffkandidaten des Unternehmens, PALI-2108, und dessen potenzielle Bedeutung f眉r die FSCD-Therapie.
Dr. Feagan, Professor f眉r Medizin an der Western University und Senior Scientific Director bei Alimentiv, Inc., sprach 眉ber den erheblichen ungedeckten Bedarf in der FSCD-Behandlung und hob den neuartigen Ansatz von PALI-2108 hervor. Der Kandidat ist darauf ausgelegt, eine lokalisierte Behandlung zu bieten, die Nebenwirkungen reduziert und gleichzeitig antiinflammatorische und antifibrotische Wirkungen erh盲lt.
- Novel localized treatment approach potentially reducing side effects
- Lead candidate addresses both inflammation and fibrotic process in FSCD
- Endorsement from leading KOL in IBD research
- Early-stage development with no efficacy data presented
- No timeline provided for clinical development
鈥� Moderated discussion with leading expert in Fibrostenotic Crohn's Disease (FSCD) and Inflammatory Bowel Diseases (IBD), Dr. Brian Feagan聽
鈥� Segment provides further insight into the need for more effective treatment options for FSCD and how PALI-2108 may become a leader in the new frontier of IBD therapeutics
鈥�
Carlsbad, CA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (鈥淧alisade,鈥� 鈥淧alisade Bio,鈥� or the 鈥淐ompany鈥�), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced the release of a聽 featuring Dr. Brian G. Feagan, MD, FRCPC. Dr. Feagan is a Professor of Medicine, Epidemiology & Biostatistics at Western University, a practicing gastroenterologist at London Health Sciences Centre, and Senior Scientific Director at Alimentiv, Inc. He is a founding member of the Stenosis Therapy and Antifibrotic Research (STAR) Consortium, the founder of Robarts Clinical Trials (now Alimentiv), and globally recognized leaders in IBD clinical research. Dr. Feagan has directed more than 140 randomized controlled trials in Crohn鈥檚 disease and ulcerative colitis, developed widely used outcome measures including the Robarts Histopathology Index, and published extensively in the field. He is internationally recognized as a leading authority in FSCD and clinical trial design.
As part of the segment, Dr. Feagan discussed FSCD and the challenges with current approved therapies, highlighting the significant unmet need for more effective therapeutics that address both inflammation and the fibrotic process. He also provided his perspective on the novel approach of PALI-2108 and how it could potentially impact the overall treatment landscape. PALI-2108鈥檚 localized approach is designed to reduce class-associated side effects while preserving anti-inflammatory and anti-fibrotic activity.
The Virtual Investor KOL Connect segment featuring Palisade Bio is now available .
For more information about PALI-2108 and the Company鈥檚 development plans, visit .
About Palisade Bio
Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to .
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
FAQ
What is PALI-2108 and how does it treat Fibrostenotic Crohn's Disease?
Who is Dr. Brian Feagan and why is his opinion on PALI-2108 significant?
What are the current challenges in treating Fibrostenotic Crohn's Disease?
Where can investors access Palisade Bio's KOL presentation about PALI-2108?
